ALK and non-small cell lung carcinoma: Umbrella trials, as noted above, are designed to evaluate multiple interventions (single agent or drug combinations) matched with the subtypes of a single disease population.6,7 For example, in the ALCHEMIST umbrella trial of NSCLC patients, two candidate biomarkers define the sub-studies: (a) anaplastic lymphoma kinase (ALK) translocations and (b) EGFR.